Compounds > pteridines

pteridines and volasertib

pteridines has been researched along with volasertib in 88 studies

Research

Studies (88)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (2.27)29.6817
2010's70 (79.55)24.3611
2020's16 (18.18)2.80

Authors

AuthorsStudies
Adolf, GR; Baum, A; Garin-Chesa, P; Grauert, M; Haslinger, C; Hoffmann, M; Quant, J; Rudolph, D; Steegmaier, M1
Schöffski, P1
Awada, A; Bartholomeus, S; Dumez, H; Fritsch, H; Gil, T; Glomb, P; Munzert, G; Schöffski, P; Taton, M; Wolter, P1
Bronk, SF; Canbay, A; Christensen, JD; Fingas, CD; Gores, GJ; Mertens, JC; Paul, A; Razumilava, N; Rizvi, SH; Sirica, AE; Sydor, S; Treckmann, JW1
Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD1
Baumann, M; Deparade, A; Eicheler, W; Krause, M; Kummer, B; Kunz-Schughart, LA; Pfitzmann, D; Yaromina, A1
Yim, H1
Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Reynolds, CP; Smith, MA1
Abbott, NJ; Bertone, P; Danovi, D; Elbatsh, AM; Ender, C; Engström, PG; Ferretti, P; Folarin, A; Gagrica, S; Georgian, A; Gogolok, S; Harvey, KJ; Paddison, PJ; Pollard, SM; Preston, JE; Smith, A; Stricker, SH; U, KP; Yu, D1
Carducci, MA; Ernstoff, MS; Fritsch, H; Lee, P; Lin, CC; Mahoney, J; Modi, S; Petrylak, DP; Pilz, K; Rosen, P; Schloss, C; Sonpavde, G; Spira, A; Stadler, WM; Su, WC; Tagawa, ST; Vaughn, DJ; Vinisko, R; Vogelzang, NJ; Zhao, C1
Cheng, AL; Fritsch, H; Hsu, CH; Huang, DC; Lin, CC; Lu, YS; Su, WC; Su, WP; Taube, T; Voss, F; Yang, JC; Yeh, KH; Yen, CJ1
Ahmad, N; Cholewa, BD; Pellitteri-Hahn, MC; Scarlett, CO1
Fiedler, W; Janning, M1
Bose, P; Grant, S1
Brandwein, JM; Döhner, H; Döhner, K; Fiedler, W; Fouillard, L; Fritsch, H; Haaland, A; Krämer, A; Lepretre, S; Lübbert, M; Maertens, J; Müller-Tidow, C; Ottmann, OG; Raffoux, E; Reman, O; Schlenk, RF; Taube, T; Turlure, P; Voss, F1
Gjertsen, BT; Schöffski, P1
Bogado, RF; Brassesco, MS; de Oliveira, HF; Pezuk, JA; Tone, LG1
Becker, S; Bug, G; Dötsch, C; Hehlgans, S; Krämer, A; Kurunci-Csacsko, E; Kuster, B; Ottmann, O; Pachl, F; Raab, M; Sanhaji, M; Strebhardt, K1
Abramson, V; Allen, EV; Arteaga, CL; Bafna, S; Balko, JM; Bhola, NE; Dugger, TC; Estrada, MV; Giltnane, JM; Jansen, VM; Mayer, I; Meszoely, I; Sanders, M; Ye, F1
Adolf, GR; Albrecht, C; Blaukopf, C; Garin-Chesa, P; Geiselmann, L; Gerlich, DW; Hofmann, MH; Impagnatiello, MA; Kraut, N; Moll, J; Reschke, M; Roth, M; Rudolph, D; Savarese, F; Sommer, C; Tontsch-Grunt, U; Wernitznig, A; Zuber, J1
Bogatyreva, L; Dragoi, D; Frey, AV; Hauschke, D; Lassmann, S; Lübbert, M; May, AM; Münch, C; Thurig, K; Wäsch, R; Werner, M1
Aftimos, PG; Awada, A; Bartholomeus, S; Berghmans, T; Cescutti, J; Costermans, J; Dumez, H; Forceville, K; Liu, D; Meeus, MA; Munzert, G; Pilz, K; Schöffski, P1
Becker, S; Helmke, C; Strebhardt, K1
Belz, K; Fulda, S; Hugle, M1
Blais, N; Chu, Q; Ellis, PM; Gu, Y; Hirsh, V; Leighl, NB; Liu, D; Pilz, K; Reaume, MN; Sadrolhefazi, B; Wierzbicki, R1
Fulda, S; Hugle, M; Romero, S; Weiß, LM1
De Smet, M; Herremans, C; Liu, D; Machiels, JP; Peeters, M; Pilz, K; Rottey, S; Specenier, P; Strelkowa, N; Surmont, V1
Cascinu, S; Clementi, L; de Braud, F; De Pas, T; Liu, D; Pilz, K; Sikken, P; Spitaleri, G1
Hsiao, SH; Hsieh, CH; Hsu, SC; Huang, CW; Huang, YH; Li, YQ; Luo, SY; Su, CY; Wu, CP1
Ando, K; Harada, A; Hata, T; Kiyoi, H; Kobayashi, Y; Miyazaki, Y; Naoe, T; Sakura, T; Taube, T; Watabe, A; Yamauchi, T1
Griffiths, EA; Talati, C; Wang, ES; Wetzler, M1
Fujiwara, Y; Harada, A; Inoue, K; Kitazono, S; Nakamichi, S; Nokihara, H; Takeuchi, Y; Tamura, T; Taube, T; Wakui, H; Yamada, Y; Yamamoto, N1
Del Campo, JM; Follana, P; Freyer, G; Garin-Chesa, P; Gladieff, L; Joly, F; Lesoin, A; Lortholary, A; Marzin, K; Nazabadioko, S; Pardo, B; Pilz, K; Pujade-Lauraine, E; Ray-Coquard, IL; Sassi, M; Selle, F; Sufliarsky, J; Tholander, B; Vergote, I; Vidal, L; Weber, B1
Abbou, S; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Laplace-Builhe, C; LE Dret, L; Molenaar, J; Vassal, G1
Cai, MC; Di, W; Gao, WQ; Gu, Z; Ji, ZL; Jing, Y; Ma, P; Peng, H; Yan, Y; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G1
Chen, JL; Chen, JP; Cheng, JC; Huang, YS; Jaw, FS; Kuo, SH; Shieh, MJ; Tsai, MH; Tsai, YC1
De Pauw, I; Deschoolmeester, V; Lardon, F; Pauwels, P; Peeters, M; Specenier, P; Van den Bossche, J; Vermorken, JB; Wouters, A1
Giri, U; Goonatilake, R; Heymach, JV; Johnson, FM; Li, L; Mino, B; Nilsson, M; Rodriguez-Canales, J; Singh, R; Tong, P; Villalobos, P; Wang, J; Wang, L; Wang, Y; Wistuba, I1
Alimova, I; Amani, V; Balakrishnan, I; Birks, D; Donson, AM; Foreman, NK; Handler, M; Harris, P; Levy, JM; Prince, EW; Venkataraman, S; Vibhakar, R1
Althoff, K; Dreesmann, S; Eggert, A; Schramm, A; Schulte, JH; Schwermer, M; Steenpass, L; Temming, P1
Friemel, A; Kreis, NN; Louwen, F; Ritter, A; Yuan, J1
Du, H; Hu, Y; Jiang, J; Li, F; Liu, H; Qing, G; Ren, P; Su, H; Xiao, D; Yue, M1
Ahmad, N; Cholewa, BD; Huang, W; Liu, X; Ndiaye, MA1
De Perrot, M; Domen, H; Hatanaka, KC; Hatanaka, Y; Hu, HP; Kaga, K; Kaji, M; Kanno, H; Kano, S; Kato, T; Lee, D; Matsuge, S; Matsui, Y; Matsuno, Y; Patel, P; Ujiie, H; Wada, H; Wu, L; Yasufuku, K; Young, AJ1
Frederick, M; Johnson, FM; Kalu, NN; Li, L; Mazumdar, T; Myers, JN; Peng, S; Pickering, CR; Sambandam, V; Shen, L; Singh, R; Tong, P; Wang, J; Zhang, M1
Duyster, J; Engelhardt, M; Felthaus, J; Follo, M; Greil, C; Klingner, K; Schnerch, D; Schüler, J; Wäsch, R; Wider, D1
Grant, S; Hawkins, E; Holkova, B; Kmieciak, M; Kolluri, A; Nguyen, T; Parker, R; Rahmani, M; Yazbeck, V1
Brabetz, S; Chan, JA; Herold-Mende, C; Kool, M; Korshunov, A; Mack, N; Milde, T; Pfister, SM; Schmidt, C; Schubert, NA; Schwalm, B; Selt, F; Witt, O1
Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF1
Canbay, A; Fingas, CD; Gerken, G; Jafoui, S; Mertens, JC; Paul, A; Swoboda, S; Sydor, S; Wingerter, L1
Björklund, AC; Dowdy, SF; Edsbäcker, E; Goroshchuk, O; Grandér, D; Hamil, AS; Kolosenko, I; Palm-Apergi, C1
Al Mamun Bhuyan, A; Ashiqul Haque, AKM; Cao, H; Kormann, MSD; Lang, F; Sahu, I1
Chi, H; Ge, J; Gu, P; Luo, W; Qian, Y; Wang, Y; Yao, D1
Jeon, MY; Kim, S; Kwon, TK; Min, KJ; Park, JW; Seo, SU; Woo, SM1
Akbulut, Ö; Akyol, A; Alkan, C; Borgoni, S; Durmuş, S; Eyüpoğlu, E; Kütük, Ö; Raza, U; Saatci, Ö; Şahin, Ö; Wiemann, S1
Baum, A; Engelhardt, H; Gerlach, D; Kraut, N; Rudolph, D; Savarese, F; Schweifer, N; Tontsch-Grunt, U; Waizenegger, I; Wurm, M1
Gohda, J; Inoue, JI; Ishida, T; Kawaguchi, Y; Liu, K; Suzuki, K; Takeuchi, H; Xie, X1
Brassesco, MS; Pezuk, JA; Roberto, GM; Salomão, KB; Scrideli, CA; Tone, LG1
Fritsch, H; Taube, T; Wallenstein, G; Walter, B1
Bochtler, T; Bug, G; Döhner, H; Garin-Chesa, P; Krämer, A; Krug, U; Liu, D; Lübbert, M; Müller-Tidow, C; Ottmann, OG; Schlenk, RF; Taube, T; Voss, F1
Blake, DG; Fischer, PM; McInnes, C; Mezna, M; Pearson, RJ; Westwood, NJ1
Lu, G; Wang, Y; Wu, L; Xu, L; Yao, Y; Zhou, J1
Balter, PA; Johnson, FM; Kingsley, C; Peng, S; Singh, R; Viswanath, P1
De Martino, D; Di Cristofano, A; Orlacchio, A; Ranieri, M; Yilmaz, E; Zhao, K1
Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N1
Boklan, J; Dunn, SE; Hofmann, B; Jayanthan, A; Meier-Stephenson, V; Narendran, A; Perinpanayagam, M; Trippett, TM; Truong, TH1
De Pauw, I; Deben, C; Deschoolmeester, V; Hermans, C; Jacobs, J; Lambrechts, H; Lardon, F; Pauwels, P; Peeters, M; Specenier, P; Van den Bossche, J; Vermorken, JB; Wouters, A1
Lin, F; Mahato, RI; Wang, Q; Xin, X; Yin, L1
Fang, B; Johnson, FM; Peng, S; Rao, X; Sambandam, V; Shen, L; Singh, R; Viswanath, P; Wang, J1
Bavaro, L; Castagnetti, F; Cavo, M; De Santis, S; Gugliotta, G; Mancini, M; Martelli, M; Martinelli, G; Monaldi, C; Rosti, G; Santucci, MA; Soverini, S1
Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN1
Aitken, MJL; Burks, JK; Chandra, J; Golfman, LS; Hall, MG; Herbrich, SM; Kannan, S; Konopleva, M; Mak, DH; Mullighan, CG; Song, G; Zweidler-McKay, PA1
Bassermann, F; Bellos, F; Buschhorn, L; Dill, V; Götze, KS; Haferlach, T; Hauch, RT; Hempel, D; Höckendorf, U; Höllein, A; Jilg, S; Jost, PJ; Kauschinger, J; Kern, W; Kyncl, MC; Mishra, R; Müller-Thomas, C; Odinius, TO; Peschel, C; Prodinger, PM; Schmidt, B; Slotta-Huspenina, J; Waizenegger, IC1
Eissa, LA; El-Mesery, ME; Habeeb, MR; Yousef, EH1
Chen, E; Pei, R1
Chen, S; Chen, Z; Cui, J; Jiang, L; Le, S; Liu, H; Wu, J; Xia, J; Xu, H; Yu, J; Zhang, D; Zhang, H; Zhao, J; Zou, Y1
Burgos, M; Corrales-Sanchez, V; Domingo, B; Esparis-Ogando, A; Galan-Moya, EM; Gomez-Juarez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-Lopez, MDM; Ocaña, A; Pandiella, A; Picazo-Martinez, MG1
Baulande, S; Bernard, V; Bièche, I; Bohec, M; Château-Joubert, S; Chemlali, W; Cottu, P; Coussy, F; Dahmani, A; Decaudin, D; Driouch, K; Dutertre, G; El Botty, R; Gentien, D; Huguet, L; Larcher, T; Le Romancer, M; Leal, MF; Marangoni, E; Martin, LA; Masliah-Planchon, J; Meseure, D; Montaudon, E; Morisset, L; Nemati, F; Nicolas, A; Nikitorowicz-Buniak, J; Painsec, P; Pancholi, S; Rapinat, A; Rega, C; Reyes, C; Ribas, R; Simigdala, N; Sourd, L; Tariq, Z; Vacher, S; Vincent-Salomon, A1
Borthakur, G; Cortes, J; Fagan, N; Kantarjian, H; Podoltsev, N; Rajeswari, S; Stahl, M; Taube, T; Uy, GL; Zeidan, AM1
Cho, SY; Heo, DS; Keam, B; Kim, DW; Kim, M; Kim, S; Kim, TM; Oh, Y; Park, S1
Chizhikov, E; Fritsch, H; Lang, I; Liptai, B; Liu, D; Taube, T1
Jang, HR; Kim, CH; Shin, SB; Yim, H1
Chou, TC; Huang, YT; Lin, SF; Wong, RJ; Yeh, CN1
Al-Haj, L; Al-Mohanna, F; Al-Qahtani, QH; Al-Saif, M; Al-Souhibani, N; Al-Yahya, S; Alaiya, A; Hitti, E; Khabar, KSA; Mahmoud, L; Moghrabi, WN1
Dong, Y; Gu, W; Meng, F; Wang, Z; Yuan, J; Zhao, S; Zhong, Z1
Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L1
Bian, XW; Fu, WJ; He, ZC; Liu, Q; Luo, T; Tan, J; Wang, J; Wang, YX; Xie, XQ; Yan, ZX; Yao, YL; Zhu, Z1
Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P1

Reviews

8 review(s) available for pteridines and volasertib

ArticleYear
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    The oncologist, 2009, Volume: 14, Issue:6

    Topics: Aniline Compounds; Animals; Cell Cycle Proteins; Clinical Trials as Topic; Cyclic N-Oxides; Drug Evaluation, Preclinical; Glycine; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyridines; Sulfonamides; Sulfones; Thiazolidines

2009
Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
    Anti-cancer drugs, 2013, Volume: 24, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes

2013
Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.
    Future oncology (London, England), 2014, Volume: 10, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demyelinating Diseases; Disease-Free Survival; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pteridines; Randomized Controlled Trials as Topic

2014
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
    Leukemia, 2015, Volume: 29, Issue:1

    Topics: Humans; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pteridines

2015
The role of Plk3 in oncogenesis.
    Oncogene, 2016, Jan-14, Volume: 35, Issue:2

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinogenesis; Cell Cycle Proteins; DNA Damage; Humans; Molecular Targeted Therapy; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Pteridines; Tumor Suppressor Proteins

2016
Polo-like kinase inhibitors in hematologic malignancies.
    Critical reviews in oncology/hematology, 2016, Volume: 98

    Topics: 4-Aminobenzoic Acid; Azepines; Benzazepines; Cell Cycle Proteins; Clinical Trials, Phase III as Topic; Glycine; Hematologic Neoplasms; Humans; Polo-Like Kinase 1; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Signal Transduction; Sulfones; Thiones

2016
Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Medicinal research reviews, 2016, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Randomized Controlled Trials as Topic

2016
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    Bulletin du cancer, 2021, Volume: 108, Issue:9S1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines

2021

Trials

16 trial(s) available for pteridines and volasertib

ArticleYear
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pteridines; Young Adult

2012
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
    Cancer, 2014, Apr-01, Volume: 120, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pteridines; Treatment Outcome; Urologic Neoplasms

2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    British journal of cancer, 2014, May-13, Volume: 110, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Cell Cycle Proteins; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Salvage Therapy; Taiwan; Treatment Outcome

2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
    Blood, 2014, Aug-28, Volume: 124, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pteridines; Treatment Outcome

2014
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Investigational new drugs, 2015, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Platinum; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Young Adult

2015
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Clinical lung cancer, 2015, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Dosage Calculations; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Platinum Compounds; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Survival Analysis

2015
A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4

    Topics: Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pteridines; Quinazolines; Severity of Illness Index; Thrombocytopenia

2015
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pteridines

2015
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Cancer science, 2015, Volume: 106, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Cell Cycle Proteins; Dose-Response Relationship, Drug; Female; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2015
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
    Investigational new drugs, 2016, Volume: 34, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pteridines

2016
Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-01, Volume: 34, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Pteridines; Quality of Life; Treatment Outcome

2016
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Cytarabine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pteridines; Tissue Distribution

2018
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
    British journal of haematology, 2019, Volume: 184, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pteridines; Salvage Therapy

2019
Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    European journal of haematology, 2020, Volume: 104, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cell Cycle Proteins; Female; Gene Expression Regulation, Leukemic; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Myeloid Cell Leukemia Sequence 1 Protein; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Receptor-Interacting Protein Serine-Threonine Kinases

2020
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    International journal of hematology, 2021, Volume: 113, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Decitabine; Dose-Response Relationship, Drug; Febrile Neutropenia; Feeding and Eating Disorders; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome

2021
Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.
    Clinical therapeutics, 2020, Volume: 42, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Cell Cycle Proteins; Drug Interactions; Female; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2020

Other Studies

64 other study(ies) available for pteridines and volasertib

ArticleYear
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-01, Volume: 15, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Crystallography, X-Ray; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Forkhead Transcription Factors; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Conformation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Rats; Rats, Wistar; Tissue Distribution; Xenograft Model Antitumor Assays

2009
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:4

    Topics: Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Disease Models, Animal; Enzyme Inhibitors; Hedgehog Proteins; Heterografts; Humans; Male; Protein Serine-Threonine Kinases; Pteridines; Rats; Rats, Inbred F344; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2013
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2013, Volume: 27, Issue:10

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Valproic Acid; Vorinostat

2013
Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 108, Issue:3

    Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Female; Humans; Male; Mice; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents

2013
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Mice; Mice, SCID; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Xenograft Model Antitumor Assays

2014
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Animals; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indans; Mice; Mice, Knockout; Neoplastic Stem Cells; Neural Stem Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Small Molecule Libraries; Swine; Thiophenes; Tumor Suppressor Protein p53

2013
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Journal of proteome research, 2014, Nov-07, Volume: 13, Issue:11

    Topics: Cell Cycle Proteins; Cell Line, Tumor; Heterogeneous-Nuclear Ribonucleoprotein Group C; Humans; Melanoma; Mutation; Polo-Like Kinase 1; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pteridines; Skin Neoplasms; Tandem Mass Spectrometry

2014
Orphan drug designation for pracinostat, volasertib and alvocidib in AML.
    Leukemia research, 2014, Volume: 38, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Drug Discovery; Epigenesis, Genetic; Flavonoids; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Orphan Drug Production; Piperidines; Protein Kinase Inhibitors; Pteridines; Terminology as Topic

2014
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
    Anti-cancer drugs, 2015, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Osteosarcoma; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes

2015
Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Molecular oncology, 2015, Volume: 9, Issue:1

    Topics: Cell Cycle Proteins; Cell Line, Tumor; Female; Human Umbilical Vein Endothelial Cells; Humans; M Phase Cell Cycle Checkpoints; Male; Neoplasm Proteins; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2015
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
    Cancer research, 2015, Jan-15, Volume: 75, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Breast Neoplasms; Cell Cycle Proteins; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Random Allocation; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays

2015
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 352, Issue:3

    Topics: Animals; Cell Cycle Proteins; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome; Xenograft Model Antitumor Assays

2015
Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Leukemia research, 2015, Volume: 39, Issue:4

    Topics: Aged; Aged, 80 and over; Antimitotic Agents; Apoptosis; Blast Crisis; Blotting, Western; Bone Marrow; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Male; Mitosis; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2015
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
    Cell death and differentiation, 2015, Volume: 22, Issue:12

    Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cell Cycle Checkpoints; Cell Cycle Proteins; Disease Models, Animal; Drug Synergism; Humans; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pteridines; Reactive Oxygen Species; Rhabdomyosarcoma; Signal Transduction; Transplantation, Heterologous; Tubulin Modulators; Tumor Cells, Cultured

2015
Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
    International journal of cancer, 2016, Jan-15, Volume: 138, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Humans; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA Interference; Sarcoma, Ewing; Tubulin Modulators

2016
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Molecular pharmaceutics, 2015, Nov-02, Volume: 12, Issue:11

    Topics: Adenosine Triphosphatases; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Humans; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2015
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Anticancer research, 2016, Volume: 36, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Child; Drug Synergism; Female; Flow Cytometry; Humans; Medulloblastoma; Mice; Mice, Nude; Neoplasms; Neuroblastoma; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Rhabdomyosarcoma; Sarcoma, Ewing; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays

2016
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Theranostics, 2016, Volume: 6, Issue:2

    Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma; Cell Line, Tumor; Down-Regulation; Female; Forkhead Box Protein M1; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Pteridines; Transcription Factors; Triazoles

2016
Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:4

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Heterografts; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents; Tumor Stem Cell Assay

2016
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Xenograft Model Antitumor Assays

2016
Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.
    BMC cancer, 2016, 08-18, Volume: 16

    Topics: Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Gene Expression Regulation, Neoplastic; Glioma; Humans; Oligonucleotide Array Sequence Analysis; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents; Sequence Analysis, DNA; Up-Regulation

2016
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Clinical & experimental ophthalmology, 2017, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinases; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Phosphorylation; Polo-Like Kinase 1; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Real-Time Polymerase Chain Reaction; Retinal Neoplasms; Retinoblastoma; Thiophenes; Tumor Cells, Cultured

2017
Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Adipose Tissue; Adult; Apoptosis; Benzoates; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Cellular Senescence; Female; Humans; MCF-7 Cells; Mesenchymal Stem Cells; Mitosis; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinones

2016
Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Molecular cell, 2016, 11-03, Volume: 64, Issue:3

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; N-Myc Proto-Oncogene Protein; Neuroblastoma; Neurons; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pteridines; RNA, Small Interfering; Signal Transduction; Sulfonamides; Survival Analysis; Transcription, Genetic; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2016
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Humans; Ki-67 Antigen; Melanoma; Mice, Nude; Molecular Targeted Therapy; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pteridines; S Phase Cell Cycle Checkpoints; Signal Transduction; Skin Neoplasms; Time Factors; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    International journal of oncology, 2016, Volume: 49, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering

2016
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Cancer letters, 2017, 04-28, Volume: 392

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genotype; Head and Neck Neoplasms; Humans; LIM Domain Proteins; Mice, Nude; Molecular Targeted Therapy; Mutation; Nuclear Proteins; Phenotype; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; ras Proteins; RNA Interference; Signal Transduction; Smad4 Protein; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Time Factors; Transfection; Tumor Burden; Urea; Xenograft Model Antitumor Assays

2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Oncotarget, 2017, Mar-28, Volume: 8, Issue:13

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cytarabine; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mitosis; Polo-Like Kinase 1; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome; Xenograft Model Antitumor Assays

2017
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Oncotarget, 2017, May-09, Volume: 8, Issue:19

    Topics: Animals; Caspases; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, Lethal; Genes, myc; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Mice; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sulfonamides; Xenograft Model Antitumor Assays

2017
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
    Neuro-oncology, 2017, Nov-29, Volume: 19, Issue:12

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Child, Preschool; Dactinomycin; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Pteridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
    World journal of gastroenterology, 2017, Jun-14, Volume: 23, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Cisplatin; Humans; Polo-Like Kinase 1; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pteridines; Signal Transduction

2017
RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 09-10, Volume: 261

    Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Child; Drug Delivery Systems; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Gene Silencing; Humans; M Phase Cell Cycle Checkpoints; Polo-Like Kinase 1; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA Interference; RNA, Messenger; RNA, Small Interfering

2017
Inhibition of Suicidal Erythrocyte Death by Volasertib.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 43, Issue:4

    Topics: Cell Cycle Proteins; Cell Line, Tumor; Energy Metabolism; Enzyme Inhibitors; Eryptosis; Erythrocytes; Glucose; Humans; Osmotic Pressure; Oxidative Stress; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2017
Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2018, Volume: 96, Issue:3

    Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Chromosome Segregation; DNA Breaks, Double-Stranded; DNA Repair; DNA Replication; Humans; Lung Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2018
Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.
    International journal of molecular sciences, 2017, Nov-29, Volume: 18, Issue:12

    Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Flow Cytometry; Humans; Kidney Neoplasms; Pteridines; TNF-Related Apoptosis-Inducing Ligand

2017
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Oncogene, 2018, Volume: 37, Issue:17

    Topics: Ado-Trastuzumab Emtansine; Animals; bcl-X Protein; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Maytansine; Mice; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pteridines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Xenograft Model Antitumor Assays

2018
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
    Cancer letters, 2018, 05-01, Volume: 421

    Topics: Animals; Benzene Derivatives; Cell Line; Drug Synergism; Genes, myc; Humans; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Proteins; Pteridines

2018
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
    Scientific reports, 2018, 02-23, Volume: 8, Issue:1

    Topics: Cell Line, Tumor; Drug Combinations; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Monocytes; Phorbol Esters; Primary Cell Culture; Protein Domains; Protein Kinase Inhibitors; Pteridines; RNA, Messenger; RNA, Viral; THP-1 Cells; Transcription, Genetic; Virus Activation; Virus Latency; Vorinostat

2018
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
    Anti-cancer agents in medicinal chemistry, 2018, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents; Thiophenes

2018
Strategic and Statistical Considerations on the QT Assessment of Volasertib.
    Therapeutic innovation & regulatory science, 2018, Volume: 52, Issue:4

    Topics: Clinical Trials as Topic; Drugs, Investigational; Electrocardiography; Humans; Long QT Syndrome; Prospective Studies; Protein Kinase Inhibitors; Pteridines; Research Design

2018
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
    Cell chemical biology, 2018, 09-20, Volume: 25, Issue:9

    Topics: Adenosine Triphosphate; Benzothiazoles; Binding Sites; Catalytic Domain; Cell Cycle Proteins; Drug Design; Drug Discovery; HeLa Cells; Humans; Molecular Docking Simulation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2018
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Cancer letters, 2018, 11-01, Volume: 436

    Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA Damage; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays

2018
A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice.
    Neoplasia (New York, N.Y.), 2018, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Agents; Lung Neoplasms; Male; Mice, Inbred Strains; Mice, Transgenic; Neoplasms, Experimental; Pteridines; Thoracic Cavity; Thoracic Neoplasms; Tumor Burden; X-Ray Microtomography

2018
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    Cancer letters, 2018, 12-28, Volume: 439

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoreduplication; Humans; Mice; Morpholines; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms

2018
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
    Cancer letters, 2019, 03-31, Volume: 445

    Topics: Acetanilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Drug Synergism; Gene Amplification; Heterocyclic Compounds, 3-Ring; Humans; Medulloblastoma; Mice; Protein Stability; Proto-Oncogene Proteins c-myc; Pteridines; Xenograft Model Antitumor Assays

2019
Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
    Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:6

    Topics: Apoptosis; Aurora Kinases; Azepines; Cell Cycle Proteins; Cell Proliferation; Humans; Leukemia; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Tumor Cells, Cultured

2019
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Molecular oncology, 2019, Volume: 13, Issue:5

    Topics: A549 Cells; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Hypoxia; Gene Knockdown Techniques; Humans; Lung Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Tumor Suppressor Protein p53

2019
ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
    ACS applied materials & interfaces, 2019, Apr-24, Volume: 11, Issue:16

    Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Delayed-Action Preparations; Humans; Micelles; MicroRNAs; Pancreatic Neoplasms; Polo-Like Kinase 1; Polyethylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Reactive Oxygen Species

2019
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
    EMBO molecular medicine, 2019, Volume: 11, Issue:5

    Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Humans; Integrin beta1; Lung Neoplasms; Mice, Nude; Phenotype; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pteridines; Transforming Growth Factor beta; Vimentin; Xenograft Model Antitumor Assays

2019
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Journal of experimental & clinical cancer research : CR, 2019, May-23, Volume: 38, Issue:1

    Topics: Aurora Kinase A; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Signal Transduction; Thiostrepton; Up-Regulation

2019
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
    Endocrine-related cancer, 2019, Volume: 26, Issue:8

    Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2019
Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:9

    Topics: Animals; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oncogenes; Polo-Like Kinase 1; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Receptors, Notch; RNA Interference; Xenograft Model Antitumor Assays

2019
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2020, Volume: 42, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Doxorubicin; Flavones; Hep G2 Cells; Humans; Liver Cirrhosis; Liver Neoplasms; Polo-Like Kinase 1; Proliferating Cell Nuclear Antigen; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines

2020
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    The Journal of international medical research, 2020, Volume: 48, Issue:5

    Topics: Adolescent; Adult; Aged; Burkitt Lymphoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pteridines; Retrospective Studies; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation

2020
PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation.
    Aging, 2020, 06-15, Volume: 12, Issue:12

    Topics: Actins; Allografts; Animals; Bronchiolitis Obliterans; Cell Cycle Proteins; Cell Differentiation; Cells, Cultured; Chronic Disease; Computational Biology; Disease Models, Animal; Fibrosis; Gene Knockdown Techniques; Graft Rejection; Healthy Volunteers; Humans; Lung; Lung Transplantation; Male; MAP Kinase Signaling System; Mice; Myofibroblasts; NIH 3T3 Cells; Pentose Phosphate Pathway; Phosphorylation; Polo-Like Kinase 1; Primary Cell Culture; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA-Seq; Trachea; Transforming Growth Factor beta1; Up-Regulation

2020
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Cancer letters, 2020, 10-28, Volume: 491

    Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Pteridines; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2020
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
    Nature communications, 2020, 08-13, Volume: 11, Issue:1

    Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D1; DNA Copy Number Variations; Drug Resistance, Neoplasm; Exome Sequencing; G2 Phase Cell Cycle Checkpoints; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Mice; Mice, Nude; Piperazines; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyridines

2020
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
    Cancer letters, 2020, 12-28, Volume: 495

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; GTP Phosphohydrolases; High-Throughput Screening Assays; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pteridines

2020
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
    International journal of molecular sciences, 2020, Nov-16, Volume: 21, Issue:22

    Topics: A549 Cells; Cell Cycle Proteins; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes; Ubiquitin-Specific Peptidase 7

2020
Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Cancer science, 2021, Volume: 112, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Mice; Protein Serine-Threonine Kinases; Pteridines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2021
Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
    Molecular oncology, 2021, Volume: 15, Issue:8

    Topics: 3' Untranslated Regions; Animals; Cell Cycle Proteins; Humans; Mice; Mice, Nude; Neoplasms; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA Processing, Post-Transcriptional; Tristetraprolin; Xenograft Model Antitumor Assays

2021
α
    Acta biomaterialia, 2021, 04-01, Volume: 124

    Topics: Animals; Cell Line, Tumor; Female; Humans; Integrin alpha3; Mice; Molecular Targeted Therapy; Ovarian Neoplasms; Peptides; Pteridines

2021
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:7

    Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines

2021
Calcyphosine promotes the proliferation of glioma cells and serves as a potential therapeutic target.
    The Journal of pathology, 2021, Volume: 255, Issue:4

    Topics: Adult; Aged; Animals; Apoptosis; Brain Neoplasms; Calcium-Binding Proteins; Cell Cycle; Cell Proliferation; Female; Glioma; Humans; Male; Mice; Middle Aged; Pteridines; Xenograft Model Antitumor Assays

2021